WINTON GROUP Ltd Raises Holdings in Ralliant Corporation $RAL

Key Points

• WINTON GROUP Ltd increased its Ralliant holdings by 37.6% in the second quarter, reaching 101,411 shares valued at approximately $7.47 million. Several other institutional investors also established or expanded positions.
• Ralliant reported quarterly EPS of $0.68, beating the $0.63 consensus estimate, on revenue of $567.8 million. The company issued fiscal 2026 EPS guidance of $2.76–$2.90 and declared a quarterly dividend of $0.05 per share.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and an average price target of $77.20. However, company insiders recently sold shares under pre-arranged Rule 10b5-1 plans.

WINTON GROUP Ltd grew its holdings in Ralliant Corporation (NYSE:RAL - Free Report) by 37.6% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 101,411 shares of the company's stock after buying an additional 27,704 shares during the quarter. WINTON GROUP Ltd owned about 0.09% of Ralliant worth $7,467,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of RAL. Dunhill Financial LLC acquired a new position in shares of Ralliant during the 2nd quarter worth $25,000. Global Retirement Partners LLC purchased a new position in Ralliant in the second quarter valued at about $35,000. Group One Trading LLC purchased a new position in Ralliant in the second quarter valued at about $36,000. Persistent Asset Partners Ltd acquired a new stake in shares of Ralliant during the 2nd quarter valued at approximately $37,000. Finally, Allworth Financial LP lifted its position in shares of Ralliant by 134.4% during the 4th quarter. Allworth Financial LP now owns 511 shares of the company's stock valued at $26,000 after acquiring an additional 293 shares during the period.

Insider Buying and Selling

In other news, SVP Karen Bick sold 6,062 shares of the business's stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $72.00, for a total value of $436,464.00. Following the completion of the transaction, the senior vice president owned 31,668 shares of the company's stock, valued at $2,280,096. The trade was a 16.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Tamara Newcombe sold 12,936 shares of the company's stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $71.79, for a total transaction of $928,675.44. Following the transaction, the chief executive officer directly owned 251,967 shares in the company, valued at $18,088,710.93. The trade was a 4.88% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.42% of the company's stock.

Ralliant Stock Up 3.5%

Shares of NYSE:RAL opened at $66.82 on Thursday. The company has a quick ratio of 1.00, a current ratio of 1.52 and a debt-to-equity ratio of 0.75. Ralliant Corporation has a 52-week low of $37.27 and a 52-week high of $75.41. The stock's fifty day simple moving average is $67.06 and its 200-day simple moving average is $57.63. The company has a market capitalization of $7.39 billion, a P/E ratio of -6.16, a P/E/G ratio of 2.40 and a beta of 1.54.

Ralliant (NYSE:RAL - Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The company reported $0.68 EPS for the quarter, beating analysts' consensus estimates of $0.63 by $0.05. The business had revenue of $567.80 million for the quarter. Ralliant had a positive return on equity of 14.97% and a negative net margin of 56.38%.Ralliant has set its FY 2026 guidance at 2.760-2.900 EPS and its Q3 2026 guidance at 0.720-0.780 EPS. As a group, equities research analysts forecast that Ralliant Corporation will post 2.87 earnings per share for the current fiscal year.

Ralliant Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 23rd. Stockholders of record on Tuesday, September 8th will be issued a dividend of $0.05 per share. The ex-dividend date is Tuesday, September 8th. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.3%. Ralliant's payout ratio is -1.84%.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on RAL. BMO Capital Markets initiated coverage on Ralliant in a report on Monday, July 20th. They issued a "market perform" rating and a $78.00 price target on the stock. Barclays raised their price target on Ralliant from $52.00 to $67.00 and gave the company an "overweight" rating in a research report on Wednesday, May 13th. Evercore assumed coverage on shares of Ralliant in a research report on Tuesday, June 9th. They issued an "outperform" rating and a $80.00 price objective on the stock. Truist Financial reissued a "buy" rating and issued a $82.00 price objective (up from $68.00) on shares of Ralliant in a research note on Friday, July 31st. Finally, Vertical Research downgraded shares of Ralliant from a "buy" rating to a "hold" rating and set a $65.00 target price for the company. in a report on Wednesday, May 27th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Ralliant currently has a consensus rating of "Moderate Buy" and an average target price of $77.20.

Ralliant Profile

Ralliant, Inc NYSE: RAL is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient's own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company's core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.